A hybrid filler is not a fully reversible HA filler
At Dr. Orhan Demirer’s dermatology practice in Alsancak, HArmonyCa is assessed as a specific HA–CaHA facial implant—not as a generic filler for every area. The early HA-related effect, gradual CaHA-associated response and non-reversible component are discussed together.
- Exact hybrid product, label and treatment plane confirmed
- Early HA effect separated from gradual CaHA response
- Lips, perioral, periocular and glabellar areas excluded
- Partial—not complete—hyaluronidase reversibility explained
Is the product, target, region and exit plan appropriate?
Hybrid or pure HA?
HArmonyCa contains both HA and CaHA and cannot be managed like a pure HA gel.
Support, volume or skin?
The dominant need is defined before promising “lift” or “collagen.”
Is the area permitted?
The manufacturer excludes several thin, mobile and high-risk facial regions.
What if a problem occurs?
Removing HA does not remove CaHA, so conservative indication is essential.
What is HArmonyCa Lidocaine?
HArmonyCa Lidocaine is a sterile, biodegradable hybrid facial implant. The June 2024 manufacturer instructions describe synthetic calcium hydroxylapatite microspheres suspended in a non-animal, cross-linked sodium hyaluronate gel, with lidocaine to reduce treatment discomfort.
The instructions list cross-linked sodium hyaluronate at 20 mg/mL, CaHA microspheres formulated at 55.7% and lidocaine hydrochloride at 3 mg/mL. Composition is useful for identification; it does not by itself prove that the product is appropriate for a particular face or area.
The current Türkiye product, batch, expiry and local instructions take priority. HArmonyCa should be identified by its full product name rather than described simply as “hyaluronic-acid filler.”
How do the HA and CaHA components differ?
Cross-linked hyaluronic acid
The HA gel contributes to the product’s early space-occupying, contour and support effect. Treatment-day appearance also includes placement, tissue response and temporary swelling, so it is not the settled result.
- Early visible component
- Biodegradable and temporary
- Can respond to hyaluronidase
- Does not make the whole product reversible
Calcium hydroxylapatite
CaHA microspheres provide a scaffold associated with a gradual tissue response. Published changes in density, firmness and collagen-related imaging are population observations—not a guaranteed “collagen percentage” for an individual.
- Gradual biological component
- Different behaviour from HA
- Not dissolved by hyaluronidase
- May complicate correction of an unwanted result
What does the product label actually say?
The points below summarise the English section of the manufacturer’s June 2024 instructions available in Europe. The current Türkiye version is checked for the individual product.
Facial soft-tissue augmentation
The product is intended for selected deep dermal and subdermal facial use by an authorised medical practitioner.
Use as supplied
The instructions state that it should be used as supplied; safety and efficacy after dilution have not been evaluated.
No lips, perioral, periocular or glabella
These are listed as contraindicated injection regions and should not appear as routine treatment areas.
No vessel, superficial skin or foreign body
Blood vessels, highly vascular areas, epidermis, superficial dermis and regions containing foreign bodies are excluded.
History changes eligibility
Pregnancy, breastfeeding, age under 18, autoimmune disease, active infection or inflammation and several healing, bleeding or allergy risks are listed.
Sequence instead of stacking
Controlled-trial safety with concomitant laser, peeling and some dermal therapies has not been established; the instructions specify timing precautions.
Read the manufacturer’s HArmonyCa Lidocaine Instructions for Use and official product overview. These links are informational; the product supplied in Türkiye and its current local instructions govern treatment.
Which facial regions may—or may not—be assessed?
A patient’s concern is not automatically an approved HArmonyCa target. Anatomy, current product information, treatment plane and previous material are assessed together.
May be assessed when the goal is appropriate facial soft-tissue augmentation and the proposed deep plane matches current instructions.
May be considered for proportionate support in suitable tissue; it is not a substitute for surgical removal or repositioning of tissue excess.
Cheek-to-lower-face balance may be planned without filling every line. Exact region and material amount follow examination.
Contraindicated in the manufacturer instructions. A site-specific HA filler or no procedure may be more appropriate.
Contraindicated in the manufacturer instructions. Direct tear-trough HArmonyCa is not offered as a routine option.
Injection into regions containing foreign bodies is contraindicated; previous product and current findings require clarification first.
HArmonyCa compared with HA, plain CaHA and energy devices
| Option | Main role | Time course | Important limitation |
|---|---|---|---|
| HArmonyCa | Hybrid HA–CaHA facial soft-tissue augmentation in selected regions | Early HA-related effect plus gradual CaHA-associated response | Not fully reversible; labelled facial-region exclusions apply |
| Pure HA filler | Product- and site-specific temporary volume, contour or hydration | Contour usually visible early; settling varies | Hyaluronidase management has limits and risks but acts on HA |
| Plain CaHA filler | Selected structural support or separately planned tissue-quality use | Carrier-related early change plus gradual response | Different formulation; cannot be assumed interchangeable with HArmonyCa |
| Energy-based treatment | Selected laxity, texture, pigment, vessels or deeper tissue target | Device-specific and generally gradual | Does not replace missing volume; heat and inflammation affect sequencing |
| Surgical assessment | Meaningful tissue excess or structural repositioning | Different recovery and durability | More invasive, but filler cannot reproduce surgery |
“Hybrid” does not mean superior for everyone. Pure HA may be preferable when precise, site-specific and more adjustable volume is the main priority; no filler may be preferable when the expected benefit is small.
Who may be considered—and when HArmonyCa should not proceed
Assessment may be relevant for
- An adult with a defined facial soft-tissue augmentation goal
- Selected tissue and region suitable for deep dermal or subdermal use
- Combined need for early support and gradual tissue response
- Realistic expectation of subtle, temporary and variable change
- Acceptance that the product is not fully reversible
- Ability to retain records and attend follow-up
Contraindication, postponement or another pathway
- Pregnancy, breastfeeding or age under 18
- Autoimmune disease or certain severe allergy histories
- Active infection, inflammation, herpes or abnormal skin at the site
- Relevant healing or prolonged-bleeding problem
- Lidocaine or other product-component hypersensitivity
- Target in lips, perioral, periocular or glabellar region
The manufacturer’s full contraindication list is longer than this summary. Share diagnoses, medicines, supplements, allergies, scars, dental work, fillers, threads, implants, lasers and surgery. Do not stop prescribed medicines independently.
How is a HArmonyCa plan built?
Define the concern
Volume, support, laxity, contour or skin-quality language is translated into a specific visible target.
Check medical eligibility
Contraindications, allergies, autoimmune history, medicines, infection and healing risks are reviewed.
Map previous treatment
Old filler, threads, implants, surgery, dental work and energy procedures are documented.
Examine anatomy
Skin, tissue mobility, volume, bone support and expression are viewed from several angles and in motion.
Compare materials
HArmonyCa, pure HA, plain CaHA, device, referral, observation or no treatment is considered.
Confirm product and region
Full product name, lot, expiry, local instructions, intended plane and target region are checked.
Consent to limitations
Early and gradual effects, non-reversibility, nodules and vascular or visual emergencies are discussed.
Document and review
Baseline photographs and product records are retained; further treatment follows healing and response.
Existing or unknown material changes the decision
The manufacturer states that safety and efficacy have not been evaluated in patients with other filling implants and lists regions containing foreign bodies as contraindicated.
Identify what was placed
Bring product stickers, dates, amounts, treatment sites, dissolving details and older photographs when available.
Separate anatomy from a complication
Persistent firmness, swelling, redness, tenderness, migration, colour or nodules require assessment before adding product.
Observe, investigate or treat
Records, ultrasound where relevant, medication, observation or another specialist pathway may precede any new injection.
An advertised duration expiring does not prove that previous material has disappeared. “Adding a little more” is not a diagnosis.
Hyaluronidase can affect HA—but cannot erase HArmonyCa
Hyaluronidase breaks down hyaluronic acid. It does not dissolve the CaHA microspheres in HArmonyCa or instantly reverse the tissue response associated with them. Reducing the HA portion may change volume, but it does not return the hybrid implant to “nothing.”
An unwanted contour, nodule, inflammatory reaction or vascular problem requires finding-specific management. Depending on the diagnosis, observation, medication, imaging, a targeted procedure or surgical intervention may be considered.
The live page’s former statement that HArmonyCa can simply be corrected with “safe filler reversal” has therefore been removed.
Combination treatment should be sequenced, not automatically stacked
The manufacturer states that safety with concomitant epilation, ultraviolet exposure, laser, mechanical or chemical peeling has not been evaluated in controlled clinical trials. Its instructions advise allowing at least four weeks between ultrasound-based treatment, laser or peeling and HArmonyCa.
When tissue laxity or skin quality is dominant, HIFU, laser or another device response may be assessed before adding implant volume.
Selected structural needs may be treated first when that is the main target and later procedures will not interfere with assessment.
Inflammation, bruising, healing, device depth, filler plane and clinical response may justify more than the minimum label interval.
Early appearance, gradual response and duration
The course below is illustrative. Product placement, area, swelling and individual biology change what is seen and when.
HA-related support may be visible alongside redness, tenderness, entry marks and early swelling.
Bruising, swelling, firmness and asymmetry can fluctuate; immediate photographs are not the final result.
The early tissue response settles while a gradual CaHA-associated change may begin to be assessed.
Support, tissue behaviour and maintenance need are reviewed; there is no fixed 12- or 18-month guarantee.
Encouraging product-specific studies, with important limits
Fifteen women were followed with photographs, volumetric imaging, ultrasound and elastography. Tissue changes were reported through 180 days, but the study was small and non-randomised.
A prospective open-label midface study reported effectiveness and tolerability up to one year. This supports a treatment horizon, not a personal duration promise.
Study averages cannot guarantee exact lift, collagen quantity, symmetry, duration or absence of complications for one patient.
See the 2023 prospective HArmonyCa study and the prospective post-marketing midface study. Both should be interpreted with their design and population limits.
Follow product- and finding-specific aftercare
The manufacturer advises avoiding strenuous activity, sunlight, tanning lamps and extreme weather for the first 24 hours and describes cold compresses for early redness, swelling and irritation. Dr. Orhan’s personal instructions take priority.
Do not repeatedly press, mould or massage the area unless specifically instructed for a defined finding. Contact the practice if symptoms persist beyond the expected course or worsen.
- Do not judge the result while swelling is evolving.
- Do not massage a firm area without personal advice.
- Keep entry points clean and avoid unclean tools.
- Follow instructions for makeup, exercise, heat and sun.
- Coordinate dental work and other facial procedures.
- Keep urgent contact and emergency information available.
Common reactions, delayed complications and vascular emergencies
HArmonyCa is biodegradable and non-surgical, but it is not risk-free. Reactions can occur immediately or after the early recovery period.
Common and usually temporary
Redness, swelling, pain, tenderness, itching, bruising, firmness, entry marks and early asymmetry may occur. Duration varies, and worsening or persistent symptoms need review.
Less common or serious
The manufacturer lists hematoma, seroma, extrusion, induration, pigmentation, fistula, inflammation, infection, allergy, migration, persistent nodules, granuloma, necrosis and blindness among possible adverse events.
Possible blood-flow problem
Increasing or unusual pain, blanching, white-grey-blue mottling, coolness, delayed capillary refill, blisters or a worsening dusky area requires immediate contact and urgent assessment.
Vision or neurological symptoms
Sudden blurred, double or lost vision; eye pain; eyelid droop; severe headache; weakness or speech difficulty is an emergency requiring immediate medical care.
Risk content follows the current manufacturer instructions and general FDA filler-safety guidance. The FDA link is class-level information and does not imply US approval of this specific product.
When might another option fit better?
| Dominant need | Possible assessment direction | Why HArmonyCa may be limited |
|---|---|---|
| Lip or perioral volume | Site-specific pure HA filler or no treatment | These regions are contraindicated for HArmonyCa |
| Tear trough or periocular concern | Cause-specific under-eye assessment | Periocular HArmonyCa injection is contraindicated |
| Maximum adjustability | Appropriate pure HA product | HArmonyCa’s CaHA component cannot be dissolved with hyaluronidase |
| Broad CaHA tissue-quality plan | Plain CaHA assessment where appropriate | HArmonyCa should be used as supplied; dilution has not been evaluated |
| Meaningful laxity or tissue excess | Energy-device or specialist surgical assessment | Hybrid filler cannot reproduce tissue removal or repositioning |
HArmonyCa filler prices in Izmir
Pricing depends on whether the product is appropriate, treatment area, supplied product amount, previous-filler assessment, complexity, combination sequence and follow-up.
A generic filler price does not show product authenticity, label compliance, anatomical planning, asepsis, product documentation, emergency readiness or review access. Some consultations correctly end with pure HA, another method or no injection.
Describe the main concern, previous fillers or threads and any planned dental, laser, HIFU, RF or surgical treatment.
HArmonyCa planning with Dr. Orhan Demirer
Dr. Orhan Demirer is a specialist dermatologist practising in Alsancak, Izmir. He evaluates facial support, movement, tissue thickness, skin condition, previous material and medical eligibility before recommending HArmonyCa.
The consultation may lead to HArmonyCa, a pure HA filler, plain CaHA assessment, an energy-based treatment, staged care, referral or no procedure. The aim is not to use a hybrid product everywhere; it is to select the smallest appropriate intervention.
- Specialist dermatology assessment
- Product-label and facial-region review
- Traceable product, documented amount and follow-up
- English communication for international patients
Planning HArmonyCa treatment in Izmir from abroad
Photographs cannot establish tissue plane, previous filler, medical eligibility or the safest material. Final product and treatment-region decisions are made in person.
Share preferred dates, health conditions, medicines, allergies and records of fillers, threads, dental work, lasers, RF, HIFU or surgery.
The product label, target region, alternatives, partial reversibility, expected timeline and urgent risks are discussed in English.
Allow for swelling or bruising, keep urgent contact information and agree how the settled and gradual response will be reviewed.
Do not schedule an elective injectable immediately before a flight or onward travel that would prevent observation or urgent reassessment if pain, skin colour, vision or neurological symptoms develop.
HArmonyCa filler in Izmir: patient questions
What is HArmonyCa?
HArmonyCa is a biodegradable hybrid facial filler containing cross-linked hyaluronic acid gel and calcium hydroxylapatite microspheres, with lidocaine for treatment comfort. The HA contributes to an early filling or support effect, while CaHA is associated with a gradual tissue response.
What exactly is in HArmonyCa Lidocaine?
The June 2024 manufacturer instructions list cross-linked sodium hyaluronate gel at 20 mg/mL, CaHA microspheres formulated at 55.7%, phosphate buffer and lidocaine hydrochloride at 3 mg/mL. The current product and Türkiye instructions are checked at consultation.
Is HArmonyCa the same as a standard HA filler?
No. Standard HA filler does not contain the CaHA microspheres found in HArmonyCa. Product behaviour, appropriate treatment areas, evidence and reversibility limits are therefore different.
Is HArmonyCa the same as plain CaHA filler?
No. Plain CaHA uses CaHA microspheres in a carrier gel, while HArmonyCa combines CaHA with cross-linked HA in one ready-to-use hybrid product. HArmonyCa should not be diluted or treated as interchangeable with a plain CaHA formulation.
Are HArmonyCa results immediate?
An early contour or support change may be visible from HA, product placement and temporary swelling. This is not the final result or proof of new collagen. The gradual CaHA-associated response is assessed over the following weeks and months.
When can collagen-related change be assessed?
A small prospective study reported ultrasound and elastography changes from about 60 days and confirmed changes at later follow-up through 180 days. This does not guarantee the same timing or degree of response for every patient.
How long does HArmonyCa last?
There is no guaranteed 12- or 18-month duration. A prospective post-marketing study reported benefit up to one year for selected midface augmentation, while duration in practice varies with anatomy, area, product amount, tissue and individual response.
Which areas may be assessed for HArmonyCa?
Selected facial soft-tissue augmentation in an appropriate deep dermal or subdermal plane may be considered, often in lateral facial, cheek, lower-face or jawline planning. The exact region must match current product instructions, anatomy and the individual goal.
Can HArmonyCa be used in the lips?
No. The manufacturer instructions list the lips and perioral region among the contraindicated injection areas. A site-specific HA filler or no treatment may be considered instead.
Can HArmonyCa be injected under the eyes?
No routine direct tear-trough or periocular use is presented. The manufacturer instructions contraindicate injection in the periocular area, and under-eye concerns require a separate assessment of hollowing, bags, oedema, pigment and skin quality.
Can HArmonyCa be completely dissolved?
No. Hyaluronidase can act on the HA component but does not dissolve CaHA microspheres or instantly reverse the tissue response. HArmonyCa must not be described as a fully reversible HA filler.
Can HArmonyCa be placed over previous filler?
Not automatically. The manufacturer states that safety and efficacy have not been evaluated in patients with other filling implants and contraindicates injection into regions containing foreign bodies. Product records and current findings should be reviewed before adding material.
Can HArmonyCa be combined with laser, HIFU or RF microneedling?
Treatments may be sequenced when they address separate targets, but they should not be stacked automatically. The manufacturer advises at least four weeks between ultrasound-based treatment, laser or peeling and HArmonyCa; individual healing and other device procedures may require a different interval.
Is a cannula safer than a needle for HArmonyCa?
They are different instruments and neither removes the risk of vascular occlusion. Patient selection, anatomy, product, intended layer, technique, observation and emergency readiness all contribute to safety.
What are common reactions after HArmonyCa?
Redness, swelling, pain, tenderness, itching, bruising, firmness and entry marks may occur. The manufacturer notes that typical local reactions often settle in the early recovery period, but individual duration varies and worsening symptoms require assessment.
Which symptoms need urgent medical attention?
Increasing or unusual pain, blanching, grey-blue mottling, cool skin, blistering or a worsening dusky area needs immediate assessment. Sudden visual change, eye pain, eyelid droop, severe headache, weakness or speech difficulty is an emergency.
Who should not have HArmonyCa?
The current manufacturer instructions include pregnancy, breastfeeding, age under 18, autoimmune disease, active infection or inflammation, herpes, certain healing or bleeding problems, severe allergies and sensitivity to product components or lidocaine among contraindications. A full medical review is required.
How much does HArmonyCa cost in Izmir?
The fee depends on suitability, the traceable product, treatment area, material amount, complexity, previous-filler assessment and follow-up. HArmonyCa is supplied as a product-specific system, so pricing should follow the clinical plan rather than a generic filler-unit package.
First decide whether a hybrid implant is truly the right material
A responsible HArmonyCa plan begins with the exact product, permitted region, previous material and partial-reversibility limit—not a fixed-duration promise.